Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Risperdal Lawsuits Allege Drug Is Linked to Gynecomastia, Male Breast Growth

(Medical-NewsWire.com, February 19, 2014 ) New York, NY -- In light of allegations that the antipsychotic drug Risperdal can cause abnormal breast growth in boys, the attorneys working with ClassAction.org are offering free case reviews to patients who suffered adverse effects after using the drug, as well as loved ones acting on their behalf. Lawsuits allege that Janssen Pharmaceuticals, the maker of Risperdal, knew its antipsychotic drug could put boys at risk for developing breasts (a condition known as gynecomastia), yet failed to properly warn the public about this side effect. If you or someone you know developed gynecomastia after using Risperdal, you may have legal recourse. For more information, visit http://www.classaction.org/risperdal.



In 2006, the FDA approved Risperdal for use in adolescents; however, lawsuits filed against Janssen allege that the company participated in ghostwriting campaigns to promote Risperdal for off-label uses, specifically in adolescents, long before FDA approval. According to one lawsuit, a young boy began using Risperdal in 1997 at the age of six and developed gynecomastia after using the antipsychotic drug for nearly four years. In addition to abnormal breast growth, lawsuits claim that Risperdal users suffered from other serious side effects, including problems with their endocrine systems and sexual organs. Plaintiffs allege that despite knowing that Risperdal could put boys at risk for developing gynecomastia, Janssen concealed its knowledge and continued to market the drug as a safe and effective antipsychotic.



According to the current prescribing information* for Risperdal, more than two percent of clinical trial patients developed gynecomastia after using the antipsychotic. Some believe that Risperdal may cause gynecomastia because it increases levels of a hormone known as prolactin in the body, which is only found naturally in breastfeeding women. Several studies have linked Risperdal to heightened levels of prolactin. In 2006, researchers found that when Risperdal was administered to adolescents at doses commonly used for the treatment of psychotic treatments, it could greatly increase prolactin levels. Another study from 2009 found that heightened levels of prolactin remained in patients’ bodies for at least two years after ceasing use of Risperdal.



Court documents indicate that Janssen “had a duty to provide safe prescription drugs…or proper and adequate warnings of risks and side effects” associated with its drugs, including Risperdal. If you or someone you know suffered from gynecomastia after using Janssen’s antipsychotic, you may be entitled to compensation. For more information on your potential legal rights, please click here.



About ClassAction.org



Class Action.org is dedicated to protecting consumers and investors in class actions and complex litigation throughout the United States. Class Action.org keeps consumers informed about product alerts, recalls, and emerging litigation and helps them take action against the manufacturers of defective products, drugs, and medical devices. Information about consumer fraud issues and environmental hazards is also available on the site. Visit ClassAction.org today for a no cost, no obligation case evaluation and information about your consumer rights.



*http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf

ClassAction.org

Jodie Carr

908-222-8848

pressrelease@lawyercentral.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC